260 related articles for article (PubMed ID: 22052686)
1. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.
Chopra S; Matsuyama K; Tran T; Malerich JP; Wan B; Franzblau SG; Lun S; Guo H; Maiga MC; Bishai WR; Madrid PB
J Antimicrob Chemother; 2012 Feb; 67(2):415-21. PubMed ID: 22052686
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
Mdluli K; Ma Z
Infect Disord Drug Targets; 2007 Jun; 7(2):159-68. PubMed ID: 17970226
[TBL] [Abstract][Full Text] [Related]
3. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
Chaudhari K; Surana S; Jain P; Patel HM
Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
[TBL] [Abstract][Full Text] [Related]
4. Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis.
Kashyap A; Singh PK; Silakari O
Tuberculosis (Edinb); 2018 Dec; 113():43-54. PubMed ID: 30514513
[TBL] [Abstract][Full Text] [Related]
5. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
Pantel A; Petrella S; Matrat S; Brossier F; Bastian S; Reitter D; Jarlier V; Mayer C; Aubry A
Antimicrob Agents Chemother; 2011 Oct; 55(10):4524-9. PubMed ID: 21768507
[TBL] [Abstract][Full Text] [Related]
6. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Hameed P S; Patil V; Solapure S; Sharma U; Madhavapeddi P; Raichurkar A; Chinnapattu M; Manjrekar P; Shanbhag G; Puttur J; Shinde V; Menasinakai S; Rudrapatana S; Achar V; Awasthy D; Nandishaiah R; Humnabadkar V; Ghosh A; Narayan C; Ramya VK; Kaur P; Sharma S; Werngren J; Hoffner S; Panduga V; Kumar CN; Reddy J; Kumar K N M; Ganguly S; Bharath S; Bheemarao U; Mukherjee K; Arora U; Gaonkar S; Coulson M; Waterson D; Sambandamurthy VK; de Sousa SM
J Med Chem; 2014 Jun; 57(11):4889-905. PubMed ID: 24809953
[TBL] [Abstract][Full Text] [Related]
7. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
Kashyap A; Singh PK; Silakari O
Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
Das S; Garg T; Srinivas N; Dasgupta A; Chopra S
Curr Top Med Chem; 2019; 19(8):579-593. PubMed ID: 30834837
[TBL] [Abstract][Full Text] [Related]
9. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.
Chaoui I; Oudghiri A; El Mzibri M
J Glob Antimicrob Resist; 2018 Mar; 12():171-174. PubMed ID: 29033301
[TBL] [Abstract][Full Text] [Related]
10. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.
Gl B; Rajput R; Gupta M; Dahiya P; Thakur JK; Bhatnagar R; Grover A
Biochem J; 2020 Nov; 477(21):4167-4190. PubMed ID: 33030198
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis.
Kashyap A; Singh PK; Satpati S; Verma H; Silakari O
J Cell Biochem; 2019 Mar; 120(3):3149-3159. PubMed ID: 30191589
[TBL] [Abstract][Full Text] [Related]
13. Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase.
Sriram D; Aubry A; Yogeeswari P; Fisher LM
Bioorg Med Chem Lett; 2006 Jun; 16(11):2982-5. PubMed ID: 16554151
[TBL] [Abstract][Full Text] [Related]
14. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
[TBL] [Abstract][Full Text] [Related]
15. WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis.
Ouchi Y; Mukai T; Koide K; Yamaguchi T; Park JH; Kim H; Yokoyama K; Tamaru A; Gordon SV; Nakajima C; Suzuki Y
Tuberculosis (Edinb); 2020 Jan; 120():101891. PubMed ID: 31778929
[TBL] [Abstract][Full Text] [Related]
16. Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
Kale MG; Raichurkar A; P SH; Waterson D; McKinney D; Manjunatha MR; Kranthi U; Koushik K; Jena Lk; Shinde V; Rudrapatna S; Barde S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Ghosh A; Ramya VK; Guptha S; Sharma S; Vachaspati P; Kumar KN; Giridhar J; Reddy J; Panduga V; Ganguly S; Ahuja V; Gaonkar S; Kumar CN; Ogg D; Tucker JA; Boriack-Sjodin PA; de Sousa SM; Sambandamurthy VK; Ghorpade SR
J Med Chem; 2013 Nov; 56(21):8834-48. PubMed ID: 24088190
[TBL] [Abstract][Full Text] [Related]
17. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
Fillion A; Aubry A; Brossier F; Chauffour A; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2013 Sep; 57(9):4496-500. PubMed ID: 23836169
[TBL] [Abstract][Full Text] [Related]
18. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Disratthakit A; Prammananan T; Tribuddharat C; Thaipisuttikul I; Doi N; Leechawengwongs M; Chaiprasert A
Antimicrob Agents Chemother; 2016 Sep; 60(9):5189-97. PubMed ID: 27297489
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase I and DNA gyrase as targets for TB therapy.
Nagaraja V; Godbole AA; Henderson SR; Maxwell A
Drug Discov Today; 2017 Mar; 22(3):510-518. PubMed ID: 27856347
[TBL] [Abstract][Full Text] [Related]
20. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase.
Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sheikh MG; Rane R; Basu R; Verma P; Sundaram A; Mukherjee K; de Sousa SM
J Biomol Screen; 2015 Feb; 20(2):265-74. PubMed ID: 25300873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
